Delivery Order SPE2DB20D6037-SPE2DB25FTVB6

Award Date 3/28/25
Potential Completion Date 3/31/25
Potential Value $2.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,843.20 firm fixed-price delivery order is for the supply of MICARDIS HCT 80-25 MG TABLET UD 30S, with a performance period ending on June 24, 2024. The award is part of a larger $499,999,999 indefinite delivery contract (IDC) under the DLA's SPE2DB program, which allows the agency to issue...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The contract, valued at $1,479.75, is for the delivery of MICARDIS HCT 40-12.5 MG TABLET UD 30S, a pharmaceutical product. The contract has an ultimate completion date of November 1, 2023. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a wide range...
This firm fixed-price delivery order was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $5,764.80, is for the delivery of MICARDIS HCT 80-25 MG TABLET UD 30S to fulfill the recurring medical supply needs of military health facilities worldwide. DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with the DLA under the...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $1,633.79, is for the delivery of MICARDIS HCT 80-25 MG TABLET UD 30S, a pharmaceutical product. The contract does not have a set-aside designation. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
This federal contract award was made by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,425.24 firm fixed-price delivery order is for the supply of Micardis HCT 80-12.5 mg tablets, with a completion date of June 3, 2022. The award is not associated with a set-aside designation. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $10,634.97 contract is for the delivery of Micardis HCT 80-25 mg tablet units to support the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999 through...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $2,693.16, is for the provision of Micardis HCT 80-25 mg tablets. The contract is not associated with a specific set-aside designation. However, DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
The Defense Logistics Agency Troop Support Medical awarded a firm fixed price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide MICARDIS HCT 40-12.5 mg tablets with a potential value of $1,152.96. This order is part of a larger indefinite delivery contract between DMS Pharmaceutical Group and the Defense Logistics Agency to supply a variety of pharmaceutical and medical products, including items like atropine, heparin, and midazolam hydrochloride, to...
The Defense Logistics Agency awarded a delivery order contract valued at nine hundred twenty-three dollars to DMS Pharmaceutical Group Inc. of Park Ridge, Illinois. The firm fixed price order is for the delivery of MICARDIS HCT 40-12.5 MG tablets to be completed by September 27, 2023. No set-aside designation was applied to this procurement. DMS Pharmaceutical Group Inc. will provide thirty tablets of the specified hypertension medication to the Defense Logistics Agency, the agency responsible...
This federal contract award was made by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,671.69 firm fixed-price delivery order is for the provision of Telmisartan 40 mg tablets to support the recurring pharmaceutical supply needs of U.S. military healthcare facilities. The award is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group...
  • SPE2DB20D6037
    Indefinite Delivery Contract
  • SPE2DB20D6037-SPE2DB25FTVB6
    Delivery Order

This federal contract award, with ID SPE2DB20D6037|SPE2DB25FTVB6, was issued by the Defense Logistics Agency (DLA) to the prime contractor DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is a delivery order with a firm fixed price, valued at $2,804.80, and covers the provision of the pharmaceutical product MICARDIS HCT 40-12.5 MG TABLET UD 30S.

The contract is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide.

Generated 6/27/25, 11:51 AM